Icovamenib T1D Data @ADA; Phase II COVALENT-112 & COVALENT-111 Data YE:26

Research evidence excerpt

Icovamenib T1D Data @ADA; Phase II COVALENT-112 & COVALENT-111 Data YE:26

C O M P A NY N O TE

J u n e 8 , 2 0 2 6

Icovamenib: Oral Menin Inhibitor

Diabetes pathology is characterized by a loss of functional pancreatic islet beta cells, which are

responsible for producing insulin. The loss occurs in both Type 1 and Type 2 diabetes, though the

underlying mechanisms differ. T1D is primarily an autoimmune disease, in which the immune

system destroys beta cells. T2D is marked by progressive beta cell dysfunction due to metabolic

stress, insulin resistance and islet cell inflammation. (Fife et al. Front Endocrinol 2017) The loss of

beta cell mass leads to inadequate insulin secretion and persistent hyperglycemia. Current

treatments for diabetes do not restore islet beta cells, and the cells that die are not regenerated.

However, beta cells do exhibit an adaptive ability to proliferate and increase insulin output in

response to elevated metabolic demands during pregnancy. This process is largely driven by the

placental hormones prolactin and placental lactogen, both of which signal through the prolactin

receptor (PRLR) on beta cells to activate the Jak2/Stat5 signaling cascade. (Stoffers et al. Mol

Endocrinol 2009) This pathway induces the expression of cell cycle regulators such as cyclin D2

and suppresses key inhibitors like p27Kip1 thereby promoting beta cell proliferation. Menin is a

tumor suppressor and negative regulator of beta cell growth. Under normal conditions, menin

promotes transcription of the cyclin-dependent kinase inhibitor (CDKI) proteins p18 and p27. These

CDKI proteins enforce cell cycle arrest, keeping beta cells in a quiescent state and preventing

regeneration. However, during pregnancy, prolactin signaling leads to transcriptional repression of